A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

NCT05261646 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor R \& D Strategy Adjustment

Conditions

Chemotherapy-Induced Thrombocytopenia

Interventions

DRUG: Hetrombopag
DRUG: Matching placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.